LNTH Investors Have Opportunity To Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit With The Schall Law Firm
Investors who purchased the Company's securities between February 26, 2025, and August 5, 2025, inclusive (the“Class Period”), are encouraged to contact the firm before November 10, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at , or by email at ....
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Lantheus misled investors about the growth of Pylarify, its prostate cancer imaging product. The Company touted Pylarify's market leadership position and downplayed competitive pressures that were eating into its market position. The Company suffered sharp sales declines, revealing the truth of Pylarify's position in the market. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Lantheus, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
Office: 310-301-3335
...
SOURCE:
The Schall Law Firm

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment